Excerpt from
https://www.washingtonpost.com/news/to-your-health/wp/2017/06/06/7-attention-grabbing-topics-at-the-nations-biggest-cancer-meeting/?utm_term=.8576f9221465 Hitting harder at advanced prostate cancer: The latest clinical trial results showed that adding a Johnson & Johnson drug called Zytiga, or abiraterone, to standard hormone therapy for men with newly diagnosed advanced prostate cancer reduced their chance of death by about
40 percent.
“This will clearly result in the earlier use of abiraterone and should spur rapid FDA approval for this additional indication,” said Nancy Dawson, an oncologist at Georgetown Lombardi Comprehensive Cancer Center who was not involved in the research. The medication already is approved for men whose prostate cancer worsens during the standard hormone treatment.
Have not been here for quite a while as thankfully I have been PSA 0 since RALP in 2008. Still monitoring for my dad who had targeted radiation therapy, but has recently had rising PSA's. And, still thinking, praying, and hoping the best for all newly diagnosed and still struggling with PC. Best wishes to all.
Rolerbe